A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations - Archive ouverte HAL Access content directly
Journal Articles Bioanalysis Year : 2021

A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations

(1, 2) , (1, 2, 3) , (4, 5) , (6, 7) , (2) , (5) , (8) , (2, 1, 3)
1
2
3
4
5
6
7
8
William Raoul

Abstract

Aim: Ramucirumab, an anti-VEGFR2 monoclonal antibody, has been approved for the treatment of metastatic gastric and colorectal cancer. An assay measuring ramucirumab serum concentrations was needed to investigate its pharmacokinetics and concentration-response relationship. Results: An ELISA was developed and validated according to the international guidelines for ligand-binding assays. Ramucirumab calibration standards ranged from 0.125 to 40 mg/l. Low, middle and high quality controls were spiked at 0.2, 4 and 8 mg/l, respectively. The limits of quantification were established to be 0.125 and 10 mg/l for LLOQ and ULOQ, respectively. No cross-reactivity with anti-VEGF or anti-EGFR was detected. Conclusion: This in-house-developed ELISA is sensitive, accurate, reproducible and suitable for pharmacokinetic studies of ramucirumab.
Fichier principal
Vignette du fichier
2021 01 27_2020-11-03-bio-2020-0199-blinded-highlighted.pdf (1.05 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-03186974 , version 1 (01-04-2021)

Identifiers

Cite

Celine Desvignes, David Ternant, Thierry Lecomte, Astrid Lièvre, Marc Ohresser, et al.. A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations. Bioanalysis, 2021, 13 (7), pp.565-574. ⟨10.4155/bio-2020-0199⟩. ⟨inserm-03186974⟩
105 View
84 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More